

Clinical Policy: Paricalcitol Injection (Zemplar)

Reference Number: CP.PHAR.270

Effective Date: 08.01.16

Last Review Date: 08.18

Line of Business: Medicaid, HIM–Medical Benefit

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Paricalcitol (Zemplar[®]) is a synthetically manufactured active vitamin D₂ analog.

FDA Approved Indication(s):

Paricalcitol injection (Zemplar) is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 5.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Zemplar is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Secondary Hyperparathyroidism in Chronic Kidney Disease (must meet all):

1. Diagnosis of secondary hyperparathyroidism associated with chronic kidney disease (CKD) stage 5 (defined as glomerular filtration rate <15 mL/min/1.73m² or dialysis);
2. Age ≥ 5 years;
3. Prescribed by or in consultation with a nephrologist or endocrinologist;
4. Failure of a trial of calcitriol (Rocaltrol[®]) injection at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced;
5. Paricalcitol is not prescribed concurrently with other vitamin D derivatives/analogs (e.g., calcitriol, doxercalciferol);
6. Dose does not exceed 0.24 mcg/kg every other day.

Approval Duration: 6 months

B. Other diagnoses/indications:

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

II. Continued Approval

A. Secondary Hyperparathyroidism in Chronic Kidney Disease (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Member is responding positively to therapy;

CLINICAL POLICY
Paricalcitol Injection

3. Paricalcitol is not prescribed concurrently with other vitamin D derivatives/analogs (e.g., calcitriol, doxercalciferol);
4. If request is for a dose increase, new dose does not exceed 0.24 mcg/kg every other day.

Approval Duration: 12 months

B. Other diagnoses/indications (1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CKD: chronic kidney disease
 FDA: Food and Drug Administration
 iPTH: intact parathyroid hormone

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
calcitriol injection (Rocaltrol®)	1 to 2 mcg/day IV 3 times weekly on approximately every other day; may increase by 0.5 to 1 mcg/dose at 2 to 4 week intervals to optimal response	4 mcg/day

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications

Not applicable

V. Dosage and Administration

CLINICAL POLICY
Paricalcitol Injection

Indication	Dosing Regimen	Maximum Dose
Secondary Hyperparathyroidism in CKD	Initial: 0.04 mcg/kg to 0.1 mcg/kg (2.8 – 7 mcg) administered as a bolus dose no more frequently than every other day at any time during dialysis. The dose may be increased by 2 to 4 mcg at 2- to 4- week intervals	0.24 mcg/kg

VI. Product Availability

Injection: 2 mcg/mL and 5 mcg/mL

References

1. Paricalcitol Injection Prescribing Information. Lake Forest, IL: Hospira, Inc.; February 2018. Available at <http://www.hospira.com/en/>. Accessed May 21, 2018.
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). *Kidney International Supplements* 2017; 7:1–59. Available at: <http://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf>. Accessed May 21, 2018.
3. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis.* 2002; 39(suppl 1): S1-S266.
4. Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Truven Health Analytics. Updated periodically. Accessed May 21, 2018

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J2501	Injection, paricalcitol, 1 mcg

Reviews, Revisions, and Approvals	Date	Approval Date
Policy developed.	08.16	08.16
Removed requirement for oral calcitriol use prior to Zemplar due to lack of evidence to support that both agents are of clinical parity. Added limitation regarding concurrent administration with other vitamin D derivatives/analogs.	02.17	02.17
Safety criteria was applied according to the safety guidance discussed at CPAC and endorsed by Centene Medical Affairs.	08.17	08.17

CLINICAL POLICY
Paricalcitol Injection

Reviews, Revisions, and Approvals	Date	Approval Date
3Q 2018 annual review: converted to new template; HIM Medical added; added specialist requirement; added requirement for positive response and max dose to re-auth; references reviewed and updated.	06.11.18	08.18

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

CLINICAL POLICY

Paricalcitol Injection

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.